Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Top Cited Papers
- 18 June 2020
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 382 (25), 2419-2430
- https://doi.org/10.1056/nejmoa2004413
Abstract
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficacy in patients with HER2-positive advanced gastric cancer.Keywords
Funding Information
- Daiichi Sankyo Company
This publication has 38 references indexed in Scilit:
- Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine‐linked antibody drug conjugateProtein Science, 2015
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerGastric Cancer, 2014
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III StudyJournal of Clinical Oncology, 2014
- Cathepsin B: Multiple roles in cancerProteomics – Clinical Applications, 2014
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- multifunctional enzymes in cancerNature Reviews Cancer, 2006
- Pulmonary toxicity from novel antineoplastic agentsAnnals of Oncology, 2005
- Prognostic Impact of Cysteine Proteases Cathepsin B and Cathepsin L in Pancreatic AdenocarcinomaPancreas, 2004
- A Confidence Interval for the Median Survival TimeBiometrics, 1982